CTT Pharma Gives Update On U.S. and European Patents
CTT Pharmaceutical Holdings (OTC PINK:CTTH) has received notification of an intention to grant from the European Patent Office (EPO) for additional claims to their original European Patent. The company already received an intention to grant for their micelle delivery technology but chose to further define and strengthen their patent specifically for diabetes-related drugs.
With the patent for the diabetes drug Liraglutide having expired, CTT plans to explore opportunities to utilize their micelle technology for this medication. The company believes their technology could provide an enhanced drug delivery system for pharmaceutical companies with current patented diabetes drugs and those in development.
CTT is actively strengthening their patents in both the United States and Europe and intends to file provisional patents in 2025 to further protect their technology. The company has committed to updating shareholders on additional provisional patents once filed and how they will support future development.
CTT Pharmaceutical Holdings (OTC PINK:CTTH) ha ricevuto una notifica di intenzione di concessione da parte dell'Ufficio Europeo dei Brevetti (EPO) per ulteriori rivendicazioni sul loro brevetto europeo originale. L'azienda aveva già ricevuto un'intenzione di concessione per la loro tecnologia di somministrazione in micelle, ma ha scelto di definire ulteriormente e rafforzare il proprio brevetto specificamente per farmaci correlati al diabete.
Con la scadenza del brevetto per il farmaco contro il diabete Liraglutide, CTT prevede di esplorare opportunità per utilizzare la propria tecnologia in micelle per questo medicinale. L'azienda crede che la sua tecnologia possa fornire un sistema di somministrazione del farmaco migliorato per le aziende farmaceutiche con farmaci contro il diabete attualmente brevettati e quelli in fase di sviluppo.
CTT sta attivamente rafforzando i propri brevetti sia negli Stati Uniti che in Europa e intende presentare brevetti provvisori nel 2025 per proteggere ulteriormente la propria tecnologia. L'azienda si è impegnata a aggiornare gli azionisti su ulteriori brevetti provvisori una volta presentati e su come supporteranno lo sviluppo futuro.
CTT Pharmaceutical Holdings (OTC PINK:CTTH) ha recibido una notificación de intención de concesión por parte de la Oficina Europea de Patentes (EPO) para reclamaciones adicionales a su patente europea original. La empresa ya había recibido una intención de concesión para su tecnología de entrega en micelas, pero decidió definir y fortalecer su patente específicamente para medicamentos relacionados con la diabetes.
Con la expiración de la patente del medicamento para la diabetes Liraglutide, CTT planea explorar oportunidades para utilizar su tecnología de micelas para este medicamento. La empresa cree que su tecnología podría proporcionar un sistema de entrega de medicamentos mejorado para las compañías farmacéuticas con medicamentos para la diabetes actualmente patentados y aquellos en desarrollo.
CTT está fortaleciendo activamente sus patentes tanto en Estados Unidos como en Europa e intenta presentar patentes provisionales en 2025 para proteger aún más su tecnología. La empresa se ha comprometido a actualizar a los accionistas sobre patentes provisionales adicionales una vez presentadas y cómo apoyarán el desarrollo futuro.
CTT 제약 홀딩스 (OTC PINK:CTTH)는 유럽 특허청(EPO)으로부터 원래 유럽 특허에 대한 추가 청구를 허가할 의향에 대한 통지를 받았습니다. 이 회사는 이미 미셀 전달 기술에 대한 허가 의향을 받았지만, 당뇨병 관련 약물에 대해 특허를 더욱 구체화하고 강화하기로 선택했습니다.
당뇨병 약물인 리라글루타이드의 특허가 만료됨에 따라, CTT는 이 약물에 대한 미셀 기술을 활용할 기회를 탐색할 계획입니다. 이 회사는 그들의 기술이 현재 특허된 당뇨병 약물 및 개발 중인 약물에 대해 향상된 약물 전달 시스템을 제공할 수 있다고 믿고 있습니다.
CTT는 미국과 유럽 모두에서 특허를 적극적으로 강화하고 있으며, 2025년에 기술을 더욱 보호하기 위해 임시 특허를 제출할 계획입니다. 이 회사는 제출된 임시 특허에 대해 주주들에게 추가 업데이트를 제공하고 향후 개발을 지원하는 방법에 대해 알릴 것을 약속했습니다.
CTT Pharmaceutical Holdings (OTC PINK:CTTH) a reçu une notification d'intention de concession de l'Office européen des brevets (OEB) pour des revendications supplémentaires sur son brevet européen original. L'entreprise avait déjà reçu une intention de concession pour sa technologie de livraison en micelles, mais a choisi de définir et de renforcer son brevet spécifiquement pour les médicaments liés au diabète.
Avec l'expiration du brevet du médicament contre le diabète Liraglutide, CTT prévoit d'explorer des opportunités pour utiliser sa technologie de micelles pour ce médicament. L'entreprise croit que sa technologie pourrait fournir un système de livraison de médicaments amélioré pour les entreprises pharmaceutiques disposant de médicaments contre le diabète actuellement brevetés et ceux en développement.
CTT renforce activement ses brevets aux États-Unis et en Europe et envisage de déposer des brevets provisoires en 2025 pour protéger davantage sa technologie. L'entreprise s'est engagée à tenir les actionnaires informés sur d'autres brevets provisoires une fois déposés et sur la manière dont ils soutiendront le développement futur.
CTT Pharmaceutical Holdings (OTC PINK:CTTH) hat eine Mitteilung über die Absicht zur Erteilung von Patenten vom Europäischen Patentamt (EPO) für zusätzliche Ansprüche auf ihr ursprüngliches europäisches Patent erhalten. Das Unternehmen hatte bereits eine Absichtserklärung für seine Mikellentechnologie erhalten, entschied sich jedoch, sein Patent speziell für diabetesbezogene Medikamente weiter zu definieren und zu stärken.
Da das Patent für das Diabetesmedikament Liraglutid abgelaufen ist, plant CTT, Möglichkeiten zu erkunden, ihre Mikellen-Technologie für dieses Medikament zu nutzen. Das Unternehmen glaubt, dass seine Technologie ein verbessertes Medikamentenabgabesystem für Pharmaunternehmen mit derzeit patentierten Diabetesmedikamenten und solchen in der Entwicklung bieten könnte.
CTT stärkt aktiv seine Patente sowohl in den Vereinigten Staaten als auch in Europa und beabsichtigt, 2025 vorläufige Patente einzureichen, um seine Technologie weiter zu schützen. Das Unternehmen hat sich verpflichtet, die Aktionäre über zusätzliche vorläufige Patente zu informieren, sobald diese eingereicht sind, und wie sie die zukünftige Entwicklung unterstützen werden.
- Received intention to grant from European Patent Office for additional patent claims
- Opportunity to apply micelle technology to off-patent diabetes drug Liraglutide
- Potential to enhance delivery systems for current patented diabetes drugs
- Plans to strengthen patent portfolio in US and Europe with new filings in 2025
- None.
TAMPA, FL / ACCESS Newswire / February 25, 2025 / CTT Pharmaceutical Holdings, Inc. (OTC PINK:CTTH) has received notification of an intention to grant from the European Patent Office(EPO) for additional claims to our original European Patent. CTT Pharma already received an intention to grant from the EPO for our micelle delivery but opted to further define and strengthen our patent for diabetes related drugs. Since, the patent for the diabetes drug Liraglutide has expired CTT will seek to find opportunities to utilize our micelle technology for Liraglutide. CTT also believes our technology could offer an enhanced drug delivery system for pharmaceutical companies with current diabetes drugs that are patented and for drugs in development. Furthermore, CTT is actively working on strengthening our patents in the United States and Europe and will look to file provisional patents in 2025 to continue to protect and strengthen our technology. CTT will update shareholders on additional provisional patents once they are filed and how they will be used to help with future development.
Contact:
CTT Pharma - 813-606-0060
SOURCE: CTT Pharmaceutical Holdings, Inc.
View the original press release on ACCESS Newswire
FAQ
What patent approval did CTT Pharma (CTTH) recently receive from the European Patent Office?
How does CTT Pharma (CTTH) plan to use their micelle technology with Liraglutide?
What are CTT Pharma's (CTTH) patent expansion plans for 2025?
What market opportunity is CTT Pharma (CTTH) targeting with their micelle technology?
How will CTT Pharma's (CTTH) patent strategy affect their future development?
